Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14144MR)

This product GTTS-WQ14144MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14144MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14014MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ8573MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ735MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ9521MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ5409MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ15405MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ14990MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW